Tekla Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $116M | Buy |
161,418
+18,365
| +13% | +$14.2M | 4.54% | 4 |
|
|
2023
Q1 | $118M | Buy |
143,053
+22,191
| +18% | +$16.7M | 4.48% | 3 |
|
|
2022
Q4 | $87.2M | Buy |
120,862
+11,800
| +11% | +$8.71M | 3.29% | 7 |
|
|
2022
Q3 | $75.1M | Sell |
109,062
-33,802
| -24% | -$21.3M | 3.08% | 8 |
|
|
2022
Q2 | $84.5M | Sell |
142,864
-3,336
| -2% | -$2.17M | 3.32% | 7 |
|
|
2022
Q1 | $102M | Buy |
146,200
+3,151
| +2% | +$1.99M | 3.59% | 3 |
|
|
2021
Q4 | $90.3M | Sell |
143,049
-4,966
| -3% | -$3.05M | 2.91% | 7 |
|
|
2021
Q3 | $89.6M | Buy |
148,015
+9,883
| +7% | +$6.14M | 2.88% | 6 |
|
|
2021
Q2 | $77.2M | Sell |
138,132
-15,373
| -10% | -$7.79M | 2.51% | 10 |
|
|
2021
Q1 | $72.6M | Sell |
153,505
-25,880
| -14% | -$12.6M | 2.5% | 9 |
|
|
2020
Q4 | $86.7M | Sell |
179,385
-28,003
| -14% | -$15.1M | 3.05% | 3 |
|
|
2020
Q3 | $116M | Buy |
207,388
+19,453
| +10% | +$11.8M | 4.35% | 2 |
|
|
2020
Q2 | $117M | Buy |
187,935
+17,057
| +10% | +$9.68M | 4.46% | 4 |
|
|
2020
Q1 | $83.4M | Sell |
170,878
-30,399
| -15% | -$12.5M | 3.77% | 6 |
|
|
2019
Q4 | $75.6M | Buy |
201,277
+41,619
| +26% | +$14M | 2.86% | 9 |
|
|
2019
Q3 | $44.3M | Sell |
159,658
-7,310
| -4% | -$2.16M | 1.93% | 12 |
|
|
2019
Q2 | $52.3M | Buy |
166,968
+25,436
| +18% | +$8.47M | 2.13% | 12 |
|
|
2019
Q1 | $58.1M | Buy |
141,532
+5,110
| +4% | +$2.1M | 2.36% | 11 |
|
|
2018
Q4 | $51M | Sell |
136,422
-9,815
| -7% | -$3.59M | 2.18% | 11 |
|
|
2018
Q3 | $59.1M | Hold |
146,237
| – | – | 2.14% | 12 |
|
|
2018
Q2 | $50.5M | Buy |
146,237
+6,677
| +5% | +$2.09M | 1.91% | 13 |
|
|
2018
Q1 | $48.1M | Sell |
139,560
-30,956
| -18% | -$10.8M | 1.87% | 14 |
|
|
2017
Q4 | $64.1M | Hold |
170,516
| – | – | 2.47% | 12 |
|
|
2017
Q3 | $76.2M | Sell |
170,516
-17,150
| -9% | -$8.16M | 2.73% | 10 |
|
|
2017
Q2 | $92.2M | Hold |
187,666
| – | – | 3.41% | 8 |
|
|
2017
Q1 | $72.7M | Hold |
187,666
| – | – | 2.82% | 11 |
|
|
2016
Q4 | $68.9M | Buy |
187,666
+33,400
| +22% | +$12.7M | 2.93% | 9 |
|
|
2016
Q3 | $62M | Hold |
154,266
| – | – | 2.38% | 10 |
|
|
2016
Q2 | $53.9M | Hold |
154,266
| – | – | 2.2% | 9 |
|
|
2016
Q1 | $55.6M | Hold |
154,266
| – | – | 2.36% | 9 |
|
|
2015
Q4 | $83.7M | Hold |
154,266
| – | – | 3.04% | 10 |
|
|
2015
Q3 | $71.8M | Sell |
154,266
-32,900
| -18% | -$17.7M | 2.58% | 11 |
|
|
2015
Q2 | $95.5M | Hold |
187,166
| – | – | 3.45% | 8 |
|
|
2015
Q1 | $84.5M | Sell |
187,166
-11,200
| -6% | -$4.75M | 3.35% | 7 |
|
|
2014
Q4 | $81.4M | Buy |
198,366
+11,200
| +6% | +$4.4M | 3.81% | 6 |
|
|
2014
Q3 | $67.5M | Sell |
187,166
-6,300
| -3% | -$2.11M | 3.16% | 6 |
|
|
2014
Q2 | $54.6M | Sell |
193,466
-17,700
| -8% | -$5.25M | 5.02% | 4 |
|
|
2014
Q1 | $63.4M | Sell |
211,166
-49,533
| -19% | -$15.3M | 6.34% | 3 |
|
|
2013
Q4 | $71.8M | Hold |
260,699
| – | – | 7.53% | 3 |
|
|
2013
Q3 | $81.6M | Sell |
260,699
-19,060
| -7% | -$5.01M | 9.08% | 2 |
|
|
2013
Q2 | $62.9M | Buy |
+279,759
| New | +$65.1M | 8.56% | 2 |
|
Other funds holding REGN
Tekla Capital Management's REGN Position: Q2 2023 in Review
Tekla Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 13% in Q2 2023, buying an estimated $14.2M and bringing the position to 161,418 shares worth $116M. The position accounts for 4.54% of the portfolio, ranked #4.
Tekla Capital Management first reported a position in REGN in Q2 2013 and has held it in 41 quarters since. The position peaked at $118M in Q1 2023. 1,166 funds tracked by Wall St. Rank hold REGN as of Q2 2023.
- Tekla Capital Management held 161,418 shares of Regeneron Pharmaceuticals worth $116M as of Q2 2023.
- Tekla Capital Management bought 18,365 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $14.2M.
- Regeneron Pharmaceuticals made up 4.54% of Tekla Capital Management's portfolio in Q2 2023, its #4 holding.
- Tekla Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
- Tekla Capital Management's Regeneron Pharmaceuticals position peaked at $118M in Q1 2023.
- 1,166 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.